Strimvelis

GENETIC4 trials

Sponsors

Fondazione Telethon

Conditions

Immune System DiseasesImmunologic Deficiency SyndromesSevere Combined Immunodeficiency Due to ADA Deficiency

Phase 4

Retroviral Insertion Site Methodology Study

WithdrawnNCT03311074

Fondazione TelethonImmune System Diseases

Start: 2020-06-25End: 2020-07-09Updated: 2024-01-29

Unknown Phase

Evaluating the Effectiveness of STRIMVELIS Risk Minimization Measures (RMMs)

CompletedNCT03232203

Fondazione TelethonSevere Combined Immunodeficiency Due to ADA Deficiency

Start: 2018-04-12End: 2021-06-25Updated: 2023-11-14

Strimvelis Registry Study to Follow-up Patients With Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID)

Enrolling by invitationNCT03478670

Fondazione TelethonImmunologic Deficiency Syndromes

Start: 2017-05-05End: 2045-12-31Target: 50Updated: 2026-05-22

Methodology Study of Retroviral Insertion Site Analysis in Strimvelis Gene Therapy

Active, not recruitingNCT04959890

Fondazione TelethonSevere Combined Immunodeficiency Due to ADA Deficiency

Start: 2021-04-23End: 2024-03-31Target: 15Updated: 2024-01-29

Related Papers

Long-term and real-world safety and efficacy of retroviral gene therapy for adenosine deaminase deficiency.

2024-02-1416 citations